|
´º½º Ȩ |
|
ÇØ¿Ü´º½º |
|
|
·ù¸ÓƼ½º¾à¹° '¹Ù¸®½ÃƼ´Õ' ¾ÆÅäÇÇ¿¡µµ È¿°ú
|
¸±¸®»ç¿Í ÀλçÀÌÆ®(Incyte Corp)»çÀÇ ·ù¸¶Æ¼½º¼º°üÀý¿° Ä¡·á ½Å¾àÀÎ '¹Ù¸®½ÃƼ´Õ(Baricitinib)' °í¿ë·®ÀÌ Áߵ ¹× ÁßÁõ ¾ÆÅäÇÇ ÇǺο° ȯÀÚÀÇ Ä¡·á¿¡¼ À§¾àº¸´Ù È¿°úÀûÀÌ.. À̹̿¬ ±âÀÚ/minx3535@korea.com | 09-18 13:40 |
|
|
|
À¯·´ÀǾàǰû, ³¼Ò¾Ï ¾à¹° niraparib ½ÂÀÎ Ãßõ
|
À¯·´ÀǾàǰû(European Medicines Agency, EMEA)ÀÌ Å×»ç·Î»çÀÇ Àç¹ß¼º ³¼Ò¾Ï Ä¡·áÁ¦ÀÎ niraparib ½ÂÀÎÀ» ÃßõÇß´Ù. 15ÀÏ(ÇöÁö½Ã°¢) ·ÎÀÌÅÍ Åë½ÅÀº À¯·´ÀǾàǰûÀÇ ¹ß.. À̹̿¬ ±âÀÚ/minx3535@korea.com | 09-18 10:04 |
|
|
|
À¯·´ÀÚ¹®À§ GSK »ïÁߺ¹ÇÕÁ¦ 'Innoviva' ½ÂÀÎ Ãßõ
|
À¯·´ÀǾàǰû(European Medicines Agency, EMEA)ÀÇ ¾à¹°»ç¿ëÀÚ¹®À§¿øȸ(Committee for Medicinal Products for Human Use, CHMP)°¡ ¼¼°¡Áö ¾à¹°À» Çϳª·Î ÇÕÄ£ GSK»çÀÇ ÈíÀÔ.. À̹̿¬ ±âÀÚ/minx3535@korea.com | 09-18 09:20 |
|
|
|
Ç׿ì¿ïÁ¦, º¹¿ë½Ã Á¶±â »ç¸Á À§Çè 33% ³ô¿©
|
¿ì¿ïÁõ Ä¡·á ¾àÀÎ Ç׿ì¿ïÁ¦¸¦ º¹¿ëÇÏ´Â »ç¶÷ÀÇ Á¶±â »ç¸Á À§ÇèÀÌ ºñº¹¿ëÀÚ¿¡ ºñÇØ ÃÖ´ë 33% ³ô´Ù´Â ¿¬±¸°á°ú°¡ ¹ßÇ¥µÆ´Ù. 14ÀÏ(ÇöÁö½Ã°¢) ¸ÞµðÄÃÀͽºÇÁ·¹½º´Â Psychot.. À̹̿¬ ±âÀÚ/minx3535@korea.com | 09-18 08:49 |
|
|
|
ÇǺΠÆÐÄ¡, Çطοî Áö¹æ ÁÙ¾îµé°Ô ÇØ
|
¹î»ì µî ¿øÄ¡¾Ê´Â Áö¹æÀ» Å¿ì±â À§ÇØ ¾à¹°ÀÌ Åõ¿©µÈ ÇǺΠÆÐÄ¡¸¦ ÀÌ¿ëÇÏ´Â °ÍÀÌ °¡´ÉÇÏ´Ù´Â »õ·Î¿î ¿¬±¸°á°ú°¡ ¹ßÇ¥µÆ´Ù. 15ÀÏ(ÇöÁö½Ã°¢) Çコµ¥ÀÌ´º½º´Â ACS Nano ÃÖ.. À̹̿¬ ±âÀÚ/minx3535@korea.com | 09-18 08:21 |
|
|
|
|
|
|
|
|